Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies
August 14, 2025
By: Ilana Kowarski and Flavia Fortes
MLex
Axinn managing partner Jeny Maier was quoted in the MLex article, "Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Informa CompLaw Antitrust West Coast Conference 2026
Speaking Engagement
Antitrust
2026 FDLI Annual Conference
Speaking Engagement
Intellectual Property
Let's Talk "About". . . That Bird?
Axinn Viewpoints
Intellectual Property
What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions
Axinn Viewpoints
Antitrust
Seven Axinn Attorneys Named to 2025 Capital Pro Bono Honor Roll
Pro Bono
Antitrust
Axinn Advises Thermo Fisher Scientific on $1.075 Billion Sale of its Microbiology Business to Astorg
Deals & Cases
Antitrust
Axinn Appoints Rachael Philbin as Chief Innovation Officer
News
Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus
Axinn Viewpoints
Intellectual Property
